Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
28 avr. 2021 07h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
27 avr. 2021 07h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Present at the Needham Healthcare Conference
08 avr. 2021 07h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
29 mars 2021 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study...
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021
15 mars 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma to Present at the Barclays Global Healthcare Conference
01 mars 2021 07h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®
01 févr. 2021 06h00 HE
|
Matinas BioPharma Holdings, Inc.
– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response...
Matinas BioPharma to Present at the ICR Conference 2021
06 janv. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...
Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
04 janv. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
07 déc. 2020 06h35 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...